DK0760811T3 - Imidazolderivater som histaminreceptor H3-modulatorer - Google Patents
Imidazolderivater som histaminreceptor H3-modulatorerInfo
- Publication number
- DK0760811T3 DK0760811T3 DK96908172.8T DK96908172T DK0760811T3 DK 0760811 T3 DK0760811 T3 DK 0760811T3 DK 96908172 T DK96908172 T DK 96908172T DK 0760811 T3 DK0760811 T3 DK 0760811T3
- Authority
- DK
- Denmark
- Prior art keywords
- histamine receptor
- imidazole derivatives
- modulators
- agonists
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9503267A FR2732017B1 (fr) | 1995-03-21 | 1995-03-21 | Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques |
PCT/FR1996/000432 WO1996029315A2 (fr) | 1995-03-21 | 1996-03-21 | Derives d'imidazole (ant)agonistes du recepteur h3 de l'histamine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0760811T3 true DK0760811T3 (da) | 2010-01-25 |
Family
ID=9477238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96908172.8T DK0760811T3 (da) | 1995-03-21 | 1996-03-21 | Imidazolderivater som histaminreceptor H3-modulatorer |
Country Status (11)
Country | Link |
---|---|
US (1) | US6248765B1 (da) |
EP (1) | EP0760811B1 (da) |
JP (1) | JPH10501001A (da) |
AT (1) | ATE449076T1 (da) |
CA (1) | CA2190865A1 (da) |
DE (1) | DE69638074D1 (da) |
DK (1) | DK0760811T3 (da) |
ES (1) | ES2334289T3 (da) |
FR (1) | FR2732017B1 (da) |
PT (1) | PT760811E (da) |
WO (1) | WO1996029315A2 (da) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2170859T3 (es) * | 1995-05-30 | 2002-08-16 | Gliatech Inc | Derivados de imidazol 1h-4(5)-sustituidos. |
US5877198A (en) * | 1996-10-17 | 1999-03-02 | Milkhaus Laboratory, Inc. | Treatment of urinary incontinence |
GB2344588B (en) * | 1997-07-25 | 2001-11-14 | Black James Foundation | 1H-4(5)-substituted imidazole derivatives their preparation and their use as histamine H 3 receptor ligands |
GB9715814D0 (en) | 1997-07-25 | 1997-10-01 | Black James Foundation | Histamine H3 receptor ligands |
US5990147A (en) * | 1997-11-07 | 1999-11-23 | Schering Corporation | H3 receptor ligands of the phenyl-alkyl-imidazoles type |
ES2188029T3 (es) * | 1997-11-07 | 2003-06-16 | Schering Corp | Fenil-alquil-imidazoles como antagonistas del receptor h3. |
US6034251A (en) * | 1997-11-07 | 2000-03-07 | Schering Corporation | Phenyl-alkyl-imidazoles |
JP2001522835A (ja) * | 1997-11-07 | 2001-11-20 | シェーリング コーポレイション | フェニル−アルキル−イミダゾール型のh3レセプターリガンド |
US6133291A (en) * | 1998-10-16 | 2000-10-17 | Schering Corporation | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists |
US6100279A (en) * | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
EP1318993B1 (en) | 2000-09-20 | 2008-08-20 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
ATE283853T1 (de) | 2000-09-20 | 2004-12-15 | Schering Corp | Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten |
MY129677A (en) | 2000-09-20 | 2007-04-30 | Schering Corp | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
DE60133014T2 (de) | 2000-09-20 | 2009-02-26 | Schering Corp. | Substituierte imidazole als duale histamin h1 und h3 agonisten oder antagonisten |
WO2002064212A1 (en) * | 2001-02-13 | 2002-08-22 | Cornell Research Foundation, Inc. | Method and compositions for reducing cardiac dysfunctions with a selective histamine h3 receptor agonist |
US20030181479A1 (en) * | 2001-11-09 | 2003-09-25 | Boehringer Ingelheim International Gmbh | Substituted imidazoles |
DE10155202A1 (de) * | 2001-11-09 | 2003-07-31 | Boehringer Ingelheim Int | Herstellung und Verwendung von substituierten Imidazolen |
FR2856596B1 (fr) * | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
ATE547404T1 (de) | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
US7880017B2 (en) | 2003-11-11 | 2011-02-01 | Allergan, Inc. | Process for the synthesis of imidazoles |
US7183305B2 (en) | 2003-11-11 | 2007-02-27 | Allergan, Inc. | Process for the synthesis of imidazoles |
EP1707203A1 (en) | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
EP1717233A1 (en) * | 2005-04-29 | 2006-11-02 | Bioprojet | Histamine H3-receptor ligands and their therapeutic application |
EP1717235A3 (en) | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
WO2007032536A1 (ja) * | 2005-09-15 | 2007-03-22 | Banyu Pharmaceutical Co., Ltd. | 脂質・糖代謝性疾患の治療剤としてのヒスタミンh3アゴニスト |
CA2637375A1 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
US20090264470A1 (en) * | 2006-02-21 | 2009-10-22 | Bennett Teresa A | CB1 Antagonists and Inverse Agonists |
JP5398177B2 (ja) * | 2007-06-06 | 2014-01-29 | エスケー化研株式会社 | 殺菌性組成物 |
US20090036426A1 (en) * | 2007-07-30 | 2009-02-05 | Ampla Pharmaceuticals Inc. | CB1 antagonists and inverse agonists |
US20110230428A1 (en) * | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
HUE034802T2 (en) | 2011-08-30 | 2018-02-28 | Chdi Foundation Inc | Kinurenin-3-monooxygenase inhibitors, pharmaceutical preparations and methods of use |
SG2014011654A (en) | 2011-08-30 | 2014-08-28 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2013147160A1 (ja) * | 2012-03-29 | 2013-10-03 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
CN103172551A (zh) * | 2013-03-29 | 2013-06-26 | 南京理工大学 | 一种h3受体pet配体的前体化合物及其合成方法 |
CN103242212B (zh) * | 2013-05-13 | 2015-11-04 | 南京理工大学 | 一种脑组胺h3受体放射性配体的前体及其制备方法 |
KR20170026633A (ko) | 2014-07-17 | 2017-03-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | Hiv-관련 장애의 치료 방법 및 치료용 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2069481B (en) * | 1980-02-13 | 1983-07-27 | Farmos Oy | Substituted imidazole derivatives |
GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
LU85747A1 (fr) * | 1985-01-28 | 1986-08-04 | Continental Pharma | Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives |
MY110108A (en) * | 1991-12-18 | 1998-01-27 | Schering Corp | Imidazolyl or imidazolylalkyl substituted with a four or five membered nitrigen containing heterocyclic ring |
ES2089782T3 (es) * | 1991-12-18 | 1996-10-01 | Schering Corp | Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos. |
FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
AU7823894A (en) * | 1993-08-27 | 1995-03-21 | Vrije Universiteit | New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor |
-
1995
- 1995-03-21 FR FR9503267A patent/FR2732017B1/fr not_active Expired - Fee Related
-
1996
- 1996-03-21 CA CA002190865A patent/CA2190865A1/fr not_active Abandoned
- 1996-03-21 AT AT96908172T patent/ATE449076T1/de active
- 1996-03-21 US US08/750,163 patent/US6248765B1/en not_active Expired - Fee Related
- 1996-03-21 EP EP96908172A patent/EP0760811B1/fr not_active Expired - Lifetime
- 1996-03-21 WO PCT/FR1996/000432 patent/WO1996029315A2/fr active Application Filing
- 1996-03-21 DE DE69638074T patent/DE69638074D1/de not_active Expired - Lifetime
- 1996-03-21 JP JP8528146A patent/JPH10501001A/ja not_active Withdrawn
- 1996-03-21 DK DK96908172.8T patent/DK0760811T3/da active
- 1996-03-21 ES ES96908172T patent/ES2334289T3/es not_active Expired - Lifetime
- 1996-03-21 PT PT96908172T patent/PT760811E/pt unknown
Also Published As
Publication number | Publication date |
---|---|
EP0760811A1 (fr) | 1997-03-12 |
PT760811E (pt) | 2010-02-10 |
FR2732017B1 (fr) | 2000-09-22 |
DE69638074D1 (de) | 2009-12-31 |
ATE449076T1 (de) | 2009-12-15 |
WO1996029315A2 (fr) | 1996-09-26 |
ES2334289T3 (es) | 2010-03-08 |
FR2732017A1 (fr) | 1996-09-27 |
JPH10501001A (ja) | 1998-01-27 |
EP0760811B1 (fr) | 2009-11-18 |
US6248765B1 (en) | 2001-06-19 |
CA2190865A1 (fr) | 1996-09-26 |
WO1996029315A3 (fr) | 1996-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0760811T3 (da) | Imidazolderivater som histaminreceptor H3-modulatorer | |
BR9914526A (pt) | Derivados de adenina | |
NO20015309L (no) | 1- (P-tienylbenzyl)-imidazoler som anginotensin-(1-7) reseptoragonister, fremgangsmåte for fremstilling og anvendelse avde samme og farmasöytiske preparater som inneholder nevnteforbindelser | |
AU4818000A (en) | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands | |
BR0010215A (pt) | Derivados de indolina como antagonistas de progesterona | |
NO20003550D0 (no) | Farmasøytiske sammensetninger og anvendelse herav | |
YU42402A (sh) | Jedinjenja karbamida koja imaju antagonističku aktivnost na muskarinski receptor | |
MY117251A (en) | Use of central cannabinoid receptor antagonists for the preparation of drugs | |
BRPI0410933A (pt) | novos antagonistas do receptor p2x7 e seu uso | |
MX9707431A (es) | Inhibidores de la proteina cinasa c. | |
PA8637601A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
BR0312020A (pt) | Método de tratamento de distúrbios, compostos, composições farmacêuticas, e, uso de um composto | |
WO1999064401A3 (en) | Imidazolyl derivatives and their use as somatostatin receptor ligands | |
NO20061737L (no) | Aminosubstituerte erylamino B2 adrenergiske receptoragonister | |
YU80902A (sh) | Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže | |
WO2002000623A3 (en) | Aryl fused substituted 4-oxy-pyridines | |
NZ516718A (en) | Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines | |
DK1019426T3 (da) | Hidtil ukendte A1-adenosinreceptoragonister og -antagonister | |
MX9801890A (es) | Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen. | |
TR199902848T2 (xx) | Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar� | |
RS20060072A (en) | Aminoquinoline derivatives and their use as adenosine a3 ligands | |
MX9605203A (es) | Nuevos compuestos glicomimeticos como antagonistas de selectinas y medicamentos que actuan inhibiendo las inflamaciones. | |
HUP0003836A2 (hu) | Lazofoxifent tartalmazó gyógyszerkészítmények | |
DK0984963T3 (da) | Hidtil ukendte forbindelser | |
AU3476599A (en) | Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists) |